Viva Biotech Holdings Management

Management criteria checks 2/4

Viva Biotech Holdings' CEO is Chen Cheney Mao, appointed in Jul 2018, has a tenure of 5.75 years. total yearly compensation is CN¥2.76M, comprised of 52.7% salary and 47.3% bonuses, including company stock and options. directly owns 8.65% of the company’s shares, worth HK$88.05M. The average tenure of the management team and the board of directors is 3 years and 5 years respectively.

Key information

Chen Cheney Mao

Chief executive officer

CN¥2.8m

Total compensation

CEO salary percentage	52.7%
CEO tenure	5.8yrs
CEO ownership	8.7%
Management average tenure	3yrs
Board average tenure	5yrs

Recent management updates

Recent updates

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

CEO Compensation Analysis

How has Chen Cheney Mao's remuneration changed compared to Viva Biotech Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CN¥116m
Sep 30 2023	n/a	n/a	-CN¥276m
Jun 30 2023	n/a	n/a	-CN¥436m
Mar 31 2023	n/a	n/a	-CN¥482m
Dec 31 2022	CN¥3m	CN¥1m	-CN¥528m
Sep 30 2022	n/a	n/a	-CN¥209m
Jun 30 2022	n/a	n/a	CN¥111m
Mar 31 2022	n/a	n/a	CN¥199m
Dec 31 2021	CN¥2m	CN¥1m	CN¥288m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥228m
Mar 31 2021	n/a	n/a	-CN¥79m
Dec 31 2020	CN¥1m	CN¥957k	-CN¥387m
Sep 30 2020	n/a	n/a	-CN¥349m
Jun 30 2020	n/a	n/a	-CN¥311m
Mar 31 2020	n/a	n/a	-CN¥23m
Dec 31 2019	CN¥1m	CN¥954k	CN¥266m

Compensation vs Market: Chen Cheney's total compensation ($USD381.18K) is above average for companies of similar size in the Hong Kong market ($USD233.03K).

Compensation vs Earnings: Chen Cheney's compensation has increased whilst the company is unprofitable.

CEO

Chen Cheney Mao (60 yo)

5.8yrs

Tenure

CN¥2,762,000

Compensation

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chen Cheney Mao	Chairman & CEO	5.8yrs	CN¥2.76m	8.65% CN¥ 88.1m
Ying Wu	Executive VP & Executive Director	5.8yrs	CN¥3.07m	0.80% CN¥ 8.2m
Delin Ren	Executive Director	less than a year	CN¥3.72m	0.69% CN¥ 7.0m
Zheren Wang	Co-Chief Financial Officer	less than a year	no data	no data
Wei Xiong	Co-Chief Financial Officer	less than a year	no data	no data
Xueheng Cheng	Chief Technology Officer	4.7yrs	no data	no data
Zhixiong Ye	Chief Scientific Officer	5.8yrs	no data	no data
Han Dai	Chief Innovation Officer & Head of Viva BioInnovator	no data	no data	no data
Jianhua Cai	Senior Vice President	no data	no data	no data
Jianguo Ma	Senior VP & CEO of Langhua Pharmaceutical	no data	no data	no data
Xianyong Bu	Senior Vice President	no data	no data	no data
Rongqiang Liu	Senior Vice President	1.4yrs	no data	no data

3.0yrs

Average Tenure

60yo

Average Age

Experienced Management: 1873's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chen Cheney Mao	Chairman & CEO	5.8yrs	CN¥2.76m	8.65% CN¥ 88.1m
Ying Wu	Executive VP & Executive Director	14.6yrs	CN¥3.07m	0.80% CN¥ 8.2m
Delin Ren	Executive Director	5.8yrs	CN¥3.72m	0.69% CN¥ 7.0m
Haiguang Wang	Independent Non-Executive Director	5yrs	CN¥216.00k	no data
Lei Fu	Independent Non-Executive Director	5yrs	CN¥216.00k	no data
Xiangrong Li	Independent Non-Executive Director	5yrs	CN¥216.00k	no data
Yuting Wu	Non-Executive Director	1.4yrs	CN¥30.00k	no data
Hui Wang	Non-Executive Director	less than a year	no data	3.97% CN¥ 40.4m

5.0yrs

Average Tenure

60yo

Average Age

Experienced Board: 1873's board of directors are considered experienced (5 years average tenure).

Viva Biotech Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

Executive VP & Executive Director recently bought HK$226k worth of stock

Less than half of directors are independent

Recent updates

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

New 90-day low: HK$6.90

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

New 90-day low: HK$7.27

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Viva Biotech Holdings Announces Resignation of MAO Jun as Non-Executive Director

New 90-day low: HK$7.38

Executive Director & CFO recently bought HK$7.0m worth of stock

New 90-day low: HK$8.18

First half earnings released

First half earnings released

Viva Biotech Holdings to Report First Half, 2020 Results on Aug 31, 2020